Medscape3d
New Data Shed Light on Who Stops Using GLP-1 Drugs, and Why
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
GLP-1 Users Are Spending Way Less on Groceries and Fast Food, According to a New Study
Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...
Fast Company12d
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
Lexaria begins biodistribution study for DehydraTECH GLP-1
Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...
Becker's Hospital Review2d
Growing evidence points to inconsistent GLP-1 adherence: 6 notes
A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...
Whose cardiovascular health do SGLT2, GLP-1 diabetes drugs benefit most?
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Scouted: ‘Nature’s Ozempic’? Experts Weigh in on the Budding GLP-1 Supplement Boom
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
Modern Healthcare2d
Digital health companies pitch employers on cutting GLP-1 costs
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), ...